$EMMA
Emmaus Life Sciences, Inc. Stock $emma

$emma Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413046007 Filed on August 14, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$50.00K	$30.00K	$30.00K
YoY Change	66.67%	0.0%	-85.0%
Cost Of Revenue	$40.00K	$40.00K	$40.00K
YoY Change	100.0%	0.0%	0.0%
Gross Profit	$10.00K	-$10.00K	$0.00
YoY Change			-100.0%
Gross Profit Margin	20.0%	-33.33%	0.0%
Selling, General & Admin	$780.0K	$736.6K	$883.5K
YoY Change	-9.3%	-16.63%	-38.22%
% of Gross Profit	7800.0%
Research & Development	$430.0K	$430.0K	$270.0K
YoY Change	152.94%	59.26%	50.0%
% of Gross Profit	4300.0%
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%
% of Gross Profit	0.0%
Operating Expenses	$1.210M	$1.205M	$1.186M
YoY Change	16.35%	1.61%	-26.32%
Operating Profit	-$1.200M	-$1.179M	-$1.153M
YoY Change	15.38%	2.25%	-20.46%
Interest Expense	-$70.00K	-$183.3K	-$767.4K
YoY Change	-101.32%	-76.11%	-132.24%
% of Operating Profit
Other Income/Expense, Net	-$5.790M	-$152.8K	$4.871M
YoY Change	-58000.0%	-103.14%	-8218.17%
Pretax Income	-$7.060M	-$1.332M	$3.718M
YoY Change	-265.73%	-135.84%	327.3%
Income Tax	$0.00	$0.00	$1.100K
% Of Pretax Income			0.03%
Net Earnings	-$7.070M	-$1.334M	$3.615M
YoY Change	-272.44%	-136.9%	315.54%
Net Earnings / Revenue	-14140.0%	-4446.67%	12050.67%
Basic Earnings Per Share		-$0.03	$1.93
Diluted Earnings Per Share	-$35.35M	-$0.03	$0.51
COMMON SHARES
Basic Shares Outstanding	81.14M shares	42.69M shares	1.874M shares
Diluted Shares Outstanding		42.69M shares	7.100M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.270M	$670.0K	$20.00K
YoY Change	12600.0%	3250.0%	-97.8%
Cash & Equivalents	$1.274M	$671.6K	$10.90K
Short-Term Investments
Other Short-Term Assets	$60.00K	$100.0K	$80.00K
YoY Change	0.0%	25.0%	-77.14%
Inventory
Prepaid Expenses
Receivables	$26.60K	$12.10K	$30.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.364M	$790.2K	$130.0K
YoY Change	1569.4%	507.85%	-90.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.80K	$19.10K	$20.00K
YoY Change	-16.0%	-4.5%	-33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.50K	$22.00K	$30.00K
YoY Change	-8.9%	-26.67%	50.0%
Total Long-Term Assets	$38.30K	$41.10K	$60.00K
YoY Change	-12.16%	-31.5%	20.0%
TOTAL ASSETS
Total Short-Term Assets	$1.364M	$790.2K	$130.0K
Total Long-Term Assets	$38.30K	$41.10K	$60.00K
Total Assets	$1.402M	$831.3K	$190.0K
YoY Change	1019.07%	337.53%	-86.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.493M	$3.000M	$2.990M
YoY Change	-19.23%	0.33%	110.56%
Accrued Expenses	$790.0K	$2.130M	$1.090M
YoY Change	-32.48%	95.41%	15.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$6.520M	$6.840M
YoY Change	-100.0%	-4.68%	135.86%
Long-Term Debt Due	$7.200K	$7.000K	$10.00K
YoY Change	38.46%	-30.0%	0.0%
Total Short-Term Liabilities	$3.556M	$11.94M	$18.10M
YoY Change	-73.05%	-34.05%	73.04%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$6.000K	$7.900K	$10.00K
YoY Change	20.0%	-21.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.556M	$11.94M	$18.10M
Total Long-Term Liabilities	$6.000K	$7.900K	$10.00K
Total Liabilities	$3.562M	$11.94M	$18.11M
YoY Change	-73.01%	-34.04%	72.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.55M	-$49.48M
YoY Change	23.9%
Common Stock	$92.70K	$49.80K
YoY Change	4778.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.160M	-$11.11M	-$17.92M
YoY Change
Total Liabilities & Shareholders Equity	$1.402M	$831.3K	$190.0K
YoY Change	1019.07%	337.53%	-86.03%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$7.070M	-$1.334M	$3.615M
YoY Change	-272.44%	-136.9%	315.54%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Operating Activities	-$1.000M	-$740.0K	-$360.0K
YoY Change	156.41%	105.56%	-59.09%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$30.00K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.590M	700.0K	200.0K
YoY Change	297.5%	250.0%	-78.95%
NET CHANGE
Cash From Operating Activities	-1.000M	-740.0K	-360.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	1.590M	700.0K	200.0K
Net Change In Cash	590.0K	-40.00K	-160.0K
YoY Change	5800.0%	-75.0%	-328.57%
FREE CASH FLOW
Cash From Operating Activities	-$1.000M	-$740.0K	-$360.0K
Capital Expenditures	$0.00	$0.00	-$30.00K
Free Cash Flow	-$1.000M	-$740.0K	-$330.0K
YoY Change	138.1%	124.24%	-62.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Trading Symbol TradingSymbol	CNSO
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81137129	shares
	dei	Entity Registrant Name EntityRegistrantName	CNS RESPONSE, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0000822370
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5900	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	14300	USD
CY2013Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	266000	USD
CY2012Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	260000	USD
CY2013Q2	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	295200	USD
CY2012Q3	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	499100	USD
CY2013Q2	cnso	Accrued Consulting Fees Liability Related Party AccruedConsultingFeesLiabilityRelatedParty	0.00	USD
CY2012Q3	cnso	Accrued Consulting Fees Liability Related Party AccruedConsultingFeesLiabilityRelatedParty	81000	USD
CY2013Q2	cnso	Subordinated Secured Debt Instrument Unamortized Discount One SubordinatedSecuredDebtInstrumentUnamortizedDiscountOne	0.00	USD
CY2012Q3	cnso	Subordinated Secured Debt Instrument Unamortized Discount One SubordinatedSecuredDebtInstrumentUnamortizedDiscountOne	416700	USD
CY2013Q2	cnso	Unsecured Debt Instrument Unamortized Discount UnsecuredDebtInstrumentUnamortizedDiscount	0.00	USD
CY2012Q3	cnso	Unsecured Debt Instrument Unamortized Discount UnsecuredDebtInstrumentUnamortizedDiscount	37500	USD
CY2013Q2	cnso	Unperfected Senior Convertible Promissory Notes Net Of Discount UnperfectedSeniorConvertiblePromissoryNotesNetOfDiscount	1300	USD
CY2012Q3	cnso	Unperfected Senior Convertible Promissory Notes Net Of Discount UnperfectedSeniorConvertiblePromissoryNotesNetOfDiscount	370200	USD
CY2013Q2	cnso	Liabilities Of Disposal Group Including Discontinued Operation Related Parties Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationRelatedPartiesCurrent	0.00	USD
CY2012Q3	cnso	Liabilities Of Disposal Group Including Discontinued Operation Related Parties Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationRelatedPartiesCurrent	89000	USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49843710	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49843710	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1914175	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1914175	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	671600	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7700	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12100	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12400	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	103400	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43700	USD
CY2013Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	3100	USD
CY2012Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	17900	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	790200	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	81700	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19100	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22000	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23600	USD
CY2013Q2	us-gaap	Assets Assets	831300	USD
CY2012Q3	us-gaap	Assets Assets	125300	USD
CY2013Q2	cnso	Accounts Payable Including Related Party Accounts Payable Current AccountsPayableIncludingRelatedPartyAccountsPayableCurrent	2997200	USD
	us-gaap	Direct Operating Costs DirectOperatingCosts	110700	USD
CY2013Q2	cnso	Research Research	53100	USD
CY2012Q2	cnso	Research Research	66300	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11936900	USD
CY2012Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	288700	USD
	cnso	Research Research	156400	USD
	cnso	Research Research	203400	USD
CY2013Q2	cnso	Product Development ProductDevelopment	376800	USD
CY2012Q2	cnso	Product Development ProductDevelopment	200900	USD
	cnso	Product Development ProductDevelopment	705400	USD
CY2012Q3	cnso	Accounts Payable Including Related Party Accounts Payable Current AccountsPayableIncludingRelatedPartyAccountsPayableCurrent	3086700	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	55800	USD
CY2012Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20600	USD
CY2013Q2	cnso	Deferred Compensation Liability Including Related Party Deferred Compensation Liability Current DeferredCompensationLiabilityIncludingRelatedPartyDeferredCompensationLiabilityCurrent	756100	USD
CY2012Q3	cnso	Deferred Compensation Liability Including Related Party Deferred Compensation Liability Current DeferredCompensationLiabilityIncludingRelatedPartyDeferredCompensationLiabilityCurrent	732700	USD
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	20000	USD
CY2012Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	104000	USD
CY2013Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1301100	USD
CY2012Q3	us-gaap	Interest Payable Current InterestPayableCurrent	1048800	USD
CY2013Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2012Q3	us-gaap	Notes Payable Current NotesPayableCurrent	200000	USD
CY2013Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2012Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	520700	USD
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7000	USD
CY2012Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5200	USD
CY2013Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	277100	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13195000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	7900	USD
CY2012Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	5000	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7900	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	11944800	USD
CY2012Q3	us-gaap	Liabilities Liabilities	13200000	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	49800	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	1900	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	-38318500	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32566700	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-49481800	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45643300	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-11113500	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-13074700	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	831300	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125300	USD
CY2013Q2	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	25900	USD
CY2012Q2	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	32800	USD
	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	83300	USD
	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	90000	USD
CY2013Q2	us-gaap	Direct Operating Costs DirectOperatingCosts	38800	USD
CY2012Q2	us-gaap	Direct Operating Costs DirectOperatingCosts	35500	USD
	us-gaap	Direct Operating Costs DirectOperatingCosts	105800	USD
	cnso	Product Development ProductDevelopment	476200	USD
CY2013Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	83400	USD
CY2012Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	223200	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	254900	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	813600	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	653200	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3407600	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1332200	USD
CY2012Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6419700	USD
	us-gaap	Operating Expenses OperatingExpenses	3861200	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1179400	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1153400	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3002900	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3771200	USD
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-183300	USD
CY2012Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-767400	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1213600	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3385000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3717500	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	660300	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1863700	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2257300	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1205300	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	1186200	USD
	us-gaap	Operating Expenses OperatingExpenses	3086200	USD
CY2013Q2	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2012Q2	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	556300	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2013Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	-30500	USD
CY2012Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	62200	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	151500	USD
CY2013Q2	cnso	Offering Costs OfferingCosts	0	USD
CY2012Q2	cnso	Offering Costs OfferingCosts	781400	USD
	cnso	Offering Costs OfferingCosts	2500	USD
	cnso	Offering Costs OfferingCosts	789100	USD
CY2013Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97600	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	918000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-152800	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-819600	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4870900	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3822500	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7178800	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1100	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2013Q2	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	-1332200	USD
CY2012Q2	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	3716400	USD
	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	-3823300	USD
	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	-7180800	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1332200	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3716400	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3823300	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7180800	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1800	USD
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-101200	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-15200	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-329500	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1334000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	3615200	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3838500	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7510300	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.98
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.83
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.00
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.18
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.01
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.03
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.52
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.83
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.00
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.18
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.01
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42691256	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1874175	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22336772	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1873902	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42691256	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7100407	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22336772	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1873902	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1010700	USD
	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	66200	USD
	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	56800	USD
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	-556300	USD
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
	cnso	Noncash Interest Expense NoncashInterestExpense	550200	USD
	cnso	Noncash Interest Expense NoncashInterestExpense	480900	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-300	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	15200	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	329500	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	10100	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	14000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	661000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2991900	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	987000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59700	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4900	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1321500	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	201700	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	242600	USD
	cnso	Increase Decrease In Deferred Compensation Exchange For Common Stock IncreaseDecreaseInDeferredCompensationExchangeForCommonStock	-178300	USD
	cnso	Increase Decrease In Deferred Compensation Exchange For Common Stock IncreaseDecreaseInDeferredCompensationExchangeForCommonStock	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	4600	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2052300	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1970700	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	0	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	4300	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1400	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21200	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1400	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25500	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4200	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4500	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1368300	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2195300	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	900	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1362700	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2726800	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2191700	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-12000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-258200	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-12000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-258200	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	663900	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-62700	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73600	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10900	USD
	us-gaap	Interest Paid Net InterestPaidNet	2557	USD
	us-gaap	Interest Paid Net InterestPaidNet	6800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
	cnso	Fair Value Of Equipment Acquired Through Lease FairValueOfEquipmentAcquiredThroughLease	0	USD
	cnso	Fair Value Of Equipment Acquired Through Lease FairValueOfEquipmentAcquiredThroughLease	20000	USD
	cnso	Placement Agent Warrants Issued PlacementAgentWarrantsIssued	66200	USD
	cnso	Placement Agent Warrants Issued PlacementAgentWarrantsIssued	56800	USD
	cnso	Offering Costs Cash Flow Noncash Investing And Financing Activities OfferingCostsCashFlowNoncashInvestingAndFinancingActivities	2500	USD
	cnso	Offering Costs Cash Flow Noncash Investing And Financing Activities OfferingCostsCashFlowNoncashInvestingAndFinancingActivities	0	USD
	cnso	Shares Issued For Promissory Notes SharesIssuedForPromissoryNotes	3375900	USD
	cnso	Shares Issued For Promissory Notes SharesIssuedForPromissoryNotes	0	USD
	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	7900	USD
	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	987000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7900	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3375900	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1362700	USD
	cnso	Adjustments To Additional Paid In Capital Placement Agent Warrants Issued AdjustmentsToAdditionalPaidInCapitalPlacementAgentWarrantsIssued	66200	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	-11421500	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1010700	USD
	cnso	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	900	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-17920200	USD
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Delaware
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1987-03-20
CY2012	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-30
CY2012Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	750000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	15000000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font size="2"> <strong>1.</strong><strong>NATURE OF OPERATIONS</strong></font> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Organization and Nature of Operations</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> CNS Response, Inc. (the “Company”) was incorporated in Delaware on March 20, 1987, under the name Age Research, Inc. Prior to January 16, 2007, CNS Response, Inc. (then called Strativation, Inc.) existed as a “shell company” with nominal assets whose sole business was to identify, evaluate and investigate various companies to acquire or with which to merge. On January 16, 2007, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CNS Response, Inc., a California corporation formed on January 11, 2000 (“CNS California”), and CNS Merger Corporation, a California corporation and the Company’s wholly-owned subsidiary (“MergerCo”) pursuant to which the Company agreed to acquire CNS California in a merger transaction wherein MergerCo would merge with and into CNS California, with CNS California being the surviving corporation (the “Merger”). On March 7, 2007, the Merger closed, CNS California became a wholly-owned subsidiary of the Company, and on the same date the corporate name was changed from Strativation, Inc. to CNS Response, Inc.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company is a clinical decision support company with a commercial neurometric platform to predict drug response for treatment of brain disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder. We have commenced a reimbursed 2,000 patient trial at Walter Reed National Military Medical Center (“Walter Reed” or “WRNMMC”) and at Fort Belvoir Community Hospital (“Fort Belvoir”) focused on patients with depression, post-traumatic stress disorder (“PTSD”) and mild traumatic brain injury (“mTBI”) in order to support clinical decisions in the treatment of depression and related disorders. We will be reimbursed by Walter Reed at our standard rate for each PEER Outcome report rendered in the study. PEER stands for Psychiatric EEG Evaluation Registry (“PEER”).</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In addition, the Company had acquired the Neuro-Therapy Clinic, Inc. (“NTC”) on January 15, 2008, which provided behavioral health care services. NTC was a center for advanced testing and treatment of neuropsychiatric problems, including learning, attentional and behavioral challenges, mild head injuries, as well as depression, anxiety, bipolar and all other common psychiatric disorders. However, due to the Company’s inability to raise sufficient funding and due to NTC’s continued operating losses, it was decided to discontinue the operations of NTC effective September 30, 2012, as the Company chose to focus its limited cash resources on the clinical trial at Walter Reed National Military Medical Center. NTC is accounted for as a discontinued operation as detailed in <em>Footnote 3</em>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On April 2, 2012, the Company announced that on March 30, 2012 it had filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) to (i) effect a 1-for-30 reverse stock split (“reverse split”) of its common stock, par value $0.001 per share (the “Common Stock”), effective at 5:00 p.m. Pacific Time on April 2, 2012 (the “Effective Time”), and (ii) simultaneously therewith reduced the number of authorized shares of Common Stock available for issuance under the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), from 750 million to <font style=" FONT-SIZE: 10pt">100</font> million. Because the Amendment did not reduce the number of authorized shares of Common Stock in the same proportion as the reverse split, the effect of the Amendment was to increase the number of shares of Common Stock available for issuance relative to the number of shares issued and outstanding.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the Effective Time, immediately and without further action by the Company’s stockholders, every 30 shares of the Company’s Common Stock issued and outstanding immediately prior to the Effective Time were automatically combined into one share of Common Stock. In the event the reverse split left a stockholder with a fraction of a share, the number of shares due to that stockholder was rounded up. Further, any options, warrants and rights outstanding as of the Effective Time that were subject to adjustment were adjusted in accordance with the terms thereof. These adjustments included, without limitation, changes to the number of shares of Common Stock that would be obtained upon exercise or conversion of such securities, and changes to the applicable exercise or purchase price.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On May 23, 2013, the Company held its 2013 annual meeting of stockholders (the “2013 Annual Meeting”), the holders of the Company’s common stock voted to elect each of the following directors to serve until the next annual meeting and until his successor is elected and qualified: Thomas Tierney, John Pappajohn, Walter Schindler, Zachary McAdoo, Richard Turner, Andrew Sassine and Robert Follman.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the 2013 Annual Meeting the shareholders also approved the following proposals:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">·</font></div> </td> <td> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”) in order to increase the number of shares of common stock, par value $0.001 per share, authorized for issuance under the Charter from <font style=" FONT-SIZE: 10pt">100,000,000</font> to <font style=" FONT-SIZE: 10pt">150,000,000.</font></font></div> </td> </tr> </table> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">·</font></div> </td> <td> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif">To amend the Company’s Charter in order to create one or more new series of preferred stock, par value $<font style=" FONT-SIZE: 10pt">0.001</font> per share, and authorize <font style=" FONT-SIZE: 10pt">15,000,000</font> shares of such preferred stock for issuance.</font></div> </td> </tr> </table> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">·</font></div> </td> <td> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif"> </font> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman, Times, Serif"><font style="FONT-SIZE: 10pt">To adopt the Company’s 2012 Omnibus Incentive Compensation Plan, as amended, to award grants of up to an aggregate of 15,000,000 shares of common stock.</font></font></div> </div> </td> </tr> </table> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY: Symbol">·</font></div> </td> <td> <div><font style="FONT-FAMILY: Times New Roman, Times, Serif"> </font> <div style="clear:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman, Times, Serif"><font style="FONT-SIZE: 10pt">To consider and provide an advisory (non-binding) vote to approve the compensation of the Company’s named executive officers as described in the proxy statement (the “Say-on-Pay Vote”) and to consider the frequency of holding the Say-on-Pay Vote (with shareholders approving a three year cycle).</font></font></div> </div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in"> <font style="FONT-SIZE: 10pt">The Company’s Charter was amended for the first two of these items effective May 31, 2013.</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in"> <font style="FONT-SIZE: 10pt"></font> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Going Concern Uncertainty</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America which contemplate continuation of the Company as a going concern. The Company has a limited operating history and its operations are subject to certain problems, expenses, difficulties, delays, complications, risks and uncertainties frequently encountered in the operation of a new business. These risks include the ability to obtain adequate financing on a timely basis, the failure to develop or supply technology or services to meet the demands of the marketplace, the failure to attract and retain qualified personnel, competition within the industry, government regulation and the general strength of regional and national economies.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s continued operating losses and limited capital raise substantial doubt about its ability to continue as a going concern. The Company has limited ability to meet its current obligations as they become due and it is in arrears on paying most of its creditors. </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> To date, the Company has financed its cash requirements primarily from debt and equity financings. It will be necessary for the Company to raise additional funds immediately to continue its operations and to raise substantial additional funds before the Company can increase demand for its PEER Online services (formerly known as rEEG services). Until it can generate a sufficient amount of revenues to finance its cash requirements, which it may never do, the Company has to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The Company’s liquidity and capital requirements depend on several factors, including the rate of market acceptance of its services, the future profitability of the Company, the rate of growth of the Company’s business and other factors described elsewhere in this report. The Company continues to explore additional sources of capital but there is substantial doubt as to whether any financing arrangement will be available in amounts and on terms acceptable to the Company to permit it to continue operations. The Company was unsuccessful in consummating the public offering of securities it had been pursuing in 2012. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of November 30, 2012 the Company closed on a $2 million round of bridge financing and has approval from the majority of note holders in each tranche to raise an additional $1 million of debt.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Between February 22, 2013 and April 1, 2013, the Company issued an aggregate of 4,180,000 shares of its common stock, par value $0.001 per share, at a per share price of $0.25, in a private placement to an aggregate of <font style=" FONT-SIZE: 10pt">19</font> accredited investors, including 450,000 shares issued to two affiliates of the Company, for gross cash proceeds to the Company of $1,045,000.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Between May 2, 2013 and June 30, 2013, the Company issued an aggregate of <font style=" FONT-SIZE: 10pt">1,710,000</font> shares of its common stock, par value $<font style=" FONT-SIZE: 10pt">0.001</font> per share at a per share price of $<font style=" FONT-SIZE: 10pt">0.25</font>, in a private placement to an aggregate of <font style=" FONT-SIZE: 10pt">9</font> accredited investors for gross cash proceeds to the Company of $<font style=" FONT-SIZE: 10pt">427,500</font>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="TEXT-INDENT: 0.5in; MARGIN: 0in" size="2">The private placements were made pursuant to an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D thereunder, as the shares of common stock were issued to accredited investors, without a view to distribution, and not through any general solicitation or advertisement. The shares of common stock have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</font></div> </div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, doubtful accounts, intangible assets, income taxes, valuation of equity instruments, accrued liabilities, contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates.</div> </div>
CY2013Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	6522600	USD
CY2013Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	421600	USD
CY2012	us-gaap	Debt Instrument Interest Rate Effective Percentage Rate Range Maximum DebtInstrumentInterestRateEffectivePercentageRateRangeMaximum	0.09	pure
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	556300	USD
CY2013Q2	cnso	Warrant Liability WarrantLiability	0	USD
CY2013Q2	cnso	Debt Conversion Option Liability DebtConversionOptionLiability	0	USD
CY2012Q3	cnso	Warrant Liability WarrantLiability	520700	USD
CY2012	cnso	Shares Authorized Reduction Shares SharesAuthorizedReductionShares	100000000	shares
CY2013Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2012Q3	cnso	Debt Conversion Option Liability DebtConversionOptionLiability	0	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	97600	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	918000	USD
	us-gaap	Depreciation Depreciation	8500	USD
	us-gaap	Depreciation Depreciation	12700	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58500	USD
CY2012Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	46400	USD
	us-gaap	Advertising Expense AdvertisingExpense	23300	USD
	us-gaap	Advertising Expense AdvertisingExpense	93100	USD
	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line basis
CY2013Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1300	USD
CY2012Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	556300	USD
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2013Q2	cnso	Total Stock Shares Authorized TotalStockSharesAuthorized	165000000	shares
CY2013Q2	cnso	Common Stock Shares Authorized Increased Number CommonStockSharesAuthorizedIncreasedNumber	150000000	shares
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	15000	USD
	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	36700	USD
CY2013Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2000000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5500000	shares
CY2013Q1	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	283400	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6132	shares
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1063500	USD
	cnso	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	67170	shares
CY2013Q2	cnso	Warrants Outstanding WarrantsOutstanding	1445556	shares
CY2013Q2	cnso	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	3.13
CY2012Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	333334	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	42670	shares
CY2012Q1	cnso	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedExercisePrice	3.00
	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	319100	USD
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	293500	USD
CY2012Q2	us-gaap	Share Based Compensation ShareBasedCompensation	340200	USD
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	546746	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.08
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	5395000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04718
CY2012Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2152	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.10
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5939594	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.61
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3810000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.06
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9749594	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9749594	shares
CY2011Q3	cnso	Warrants Outstanding WarrantsOutstanding	980390	shares
CY2012	cnso	Warrants Expired WarrantsExpired	175195	shares
CY2012Q3	cnso	Warrants Outstanding WarrantsOutstanding	2164440	shares
	cnso	Warrants Forfeited WarrantsForfeited	1617345	shares
	cnso	Warrants Issued Exercise Price WarrantsIssuedExercisePrice	3.13
	cnso	Warrants Forfeited Exercise Price WarrantsForfeitedExercisePrice	3.00
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3088100	USD
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	41873745	shares
CY2011Q2	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	125000	USD
CY2013Q2	cnso	Net Income Loss Available To Common Stockholders Basic From Continuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromContinuingOperations	-1332200	USD
CY2012Q2	cnso	Net Income Loss Available To Common Stockholders Basic From Continuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromContinuingOperations	3716400	USD
CY2013Q2	cnso	Net Income Loss Available To Common Stockholders Basic From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromDiscontinuingOperations	-1800	USD
CY2012Q2	cnso	Net Income Loss Available To Common Stockholders Basic From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromDiscontinuingOperations	-101200	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1334000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3615200	USD
CY2013Q2	cnso	Net Income Loss Available To Common Stockholders Diluted From Continuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromContinuingOperations	-1332200	USD
CY2012Q2	cnso	Net Income Loss Available To Common Stockholders Diluted From Continuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromContinuingOperations	3716400	USD
CY2013Q2	cnso	Net Income Loss Available To Common Stockholders Diluted From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromDiscontinuingOperations	-1800	USD
CY2012Q2	cnso	Net Income Loss Available To Common Stockholders Diluted From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromDiscontinuingOperations	-101200	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1334000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3615200	USD
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2012Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5226232	shares
	cnso	Net Income Loss Available To Common Stockholders Basic From Continuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromContinuingOperations	-3823300	USD
	cnso	Net Income Loss Available To Common Stockholders Basic From Continuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromContinuingOperations	-7180800	USD
	cnso	Net Income Loss Available To Common Stockholders Basic From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromDiscontinuingOperations	-15200	USD
	cnso	Net Income Loss Available To Common Stockholders Basic From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersBasicFromDiscontinuingOperations	-329500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3838500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7510300	USD
	cnso	Net Income Loss Available To Common Stockholders Diluted From Continuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromContinuingOperations	-3823300	USD
	cnso	Net Income Loss Available To Common Stockholders Diluted From Continuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromContinuingOperations	-7180800	USD
	cnso	Net Income Loss Available To Common Stockholders Diluted From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromDiscontinuingOperations	-15200	USD
	cnso	Net Income Loss Available To Common Stockholders Diluted From Discontinuing Operations NetIncomeLossAvailableToCommonStockholdersDilutedFromDiscontinuingOperations	-329500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3838500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7510300	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12400	USD
CY2012Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10900	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	35300	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	32700	USD
CY2013Q2	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	0	USD
CY2012Q2	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	16800	USD
	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	0	USD
	cnso	Disposal Group Including Discontinued Operation Rent Expense DisposalGroupIncludingDiscontinuedOperationRentExpense	49900	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due Continuing Operations OperatingLeasesFutureMinimumPaymentsDueContinuingOperations	29000	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due Discontinued Operations OperatingLeasesFutureMinimumPaymentsDueDiscontinuedOperations	0	USD
CY2013Q2	us-gaap	Contractual Obligation ContractualObligation	46300	USD
CY2013Q2	cnso	Capital Leases Future Minimum Payments Due In Less Than One Year CapitalLeasesFutureMinimumPaymentsDueInLessThanOneYear	2200	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In Less Than One Year Continuing Operations OperatingLeasesFutureMinimumPaymentsDueInLessThanOneYearContinuingOperations	29000	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In Less Than One Year Discontinued Operations OperatingLeasesFutureMinimumPaymentsDueInLessThanOneYearDiscontinuedOperations	0	USD
CY2013Q2	cnso	Contractual Obligation Due In Less Than One Year ContractualObligationDueInLessThanOneYear	31200	USD
CY2013Q2	cnso	Capital Leases Future Minimum Payments Due In One To Three Years CapitalLeasesFutureMinimumPaymentsDueInOneToThreeYears	12800	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In One To Three Years Continuing Operations OperatingLeasesFutureMinimumPaymentsDueInOneToThreeYearsContinuingOperations	0	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In One To Three Years Discontinued Operations OperatingLeasesFutureMinimumPaymentsDueInOneToThreeYearsDiscontinuedOperations	0	USD
CY2013Q2	cnso	Contractual Obligation Due In One To Three Years ContractualObligationDueInOneToThreeYears	12800	USD
CY2013Q2	cnso	Capital Leases Future Minimum Payments Due In Three To Five Years CapitalLeasesFutureMinimumPaymentsDueInThreeToFiveYears	2300	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In Three To Five Years Continuing Operations OperatingLeasesFutureMinimumPaymentsDueInThreeToFiveYearsContinuingOperations	0	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due In Three To Five Years Discontinued Operations OperatingLeasesFutureMinimumPaymentsDueInThreeToFiveYearsDiscontinuedOperations	0	USD
CY2013Q2	cnso	Contractual Obligation Due In Three To Five Years ContractualObligationDueInThreeToFiveYears	2300	USD
CY2013Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due After Five Years Continuing Operations OperatingLeasesFutureMinimumPaymentsDueAfterFiveYearsContinuingOperations	0	USD
CY2013Q2	cnso	Operating Leases Future Minimum Payments Due After Five Years Discontinued Operations OperatingLeasesFutureMinimumPaymentsDueAfterFiveYearsDiscontinuedOperations	0	USD
CY2013Q2	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0	USD
CY2013Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	17300	USD
CY2013Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6523900	USD
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	713631	shares

Files In Submission

Name	View Source	Status
0001144204-13-046007-index-headers.html	Edgar Link	pending
0001144204-13-046007-index.html	Edgar Link	pending
0001144204-13-046007.txt	Edgar Link	pending
0001144204-13-046007-xbrl.zip	Edgar Link	pending
cnso-20130630.xml	Edgar Link	completed
cnso-20130630.xsd	Edgar Link	pending
cnso-20130630_cal.xml	Edgar Link	unprocessable
cnso-20130630_def.xml	Edgar Link	unprocessable
cnso-20130630_lab.xml	Edgar Link	unprocessable
cnso-20130630_pre.xml	Edgar Link	unprocessable
ex99-4_002.jpg	Edgar Link	pending
ex99-4_003.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v351662_10q.htm	Edgar Link	pending
v351662_ex10-78.htm	Edgar Link	pending
v351662_ex10-79.htm	Edgar Link	pending
v351662_ex10-80.htm	Edgar Link	pending
v351662_ex10-81.htm	Edgar Link	pending
v351662_ex3-12.htm	Edgar Link	pending
v351662_ex31-1.htm	Edgar Link	pending
v351662_ex31-2.htm	Edgar Link	pending
v351662_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMMA
Emmaus Life Sciences, Inc. Stock $emma

2013 Q3 Form 10-Q Financial Statement

#000114420413046007 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA Emmaus Life Sciences, Inc. Stock $emma

2013 Q3 Form 10-Q Financial Statement

#000114420413046007 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA
Emmaus Life Sciences, Inc. Stock $emma